🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are on the rise around the world, with data suggesting more than 82 million instances each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of growing infection rates, escalating drug resistance and the extremely scarce available drugs at this time.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Gain Approval

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

Based on findings released by a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which involves a dual-drug approach. The trial included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have shared hope. Access to a one-pill regimen like this is hailed as a "revolutionary step" for public health efforts. This is considered essential to alleviate the strain of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea globally.